NCT03680677Recruiting
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Abramson Cancer Center at Penn Medicine
Start Date
9/21/2018
Completion Date
11/1/2026
Summary
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
Eligibility Criteria
Age Range: 60 years to No maximum
Eligibility Criteria Arm A:
* Age 60 years or older.
* New diagnosis of Acute Leukemia or MDS, or suspected diagnosis.
* Able to consent to the study.
Eligibility Criteria Arm B:
* Age 60 years or older with a hematologic malignancy.
* Plan to undergo an allogeneic blood or marrow transplantation or CAR T-cell therapy.
* Able to consent to the study.
Interventions
PROCEDURE
Bone Marrow or Peripheral Blood Graft (BMT)
OTHER
Cancer-directed Therapy or Best Supportive Care
DIAGNOSTIC_TEST
Frailty Assessment
Conditions
Leukemia, AcuteMDS
Locations
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania 19104
United States